Changes in psychopathology and peripheral inflammation in schizophrenia patients initiating treatment with second-generation antipsychotics

Neuroinflammation has been proposed as a potential factor in the pathogenesis of schizophrenia and has been suggested to be both a state and a trait measure of the disease. However, the results of previous studies are inconsistent. The aim of the present study was therefore to investigate whether peripheral inflammatory markers such as C-reactive protein (CRP), the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), and the systemic immune-inflammation index (SII) can reliably indicate disease severity in schizophrenia. 116 (52.6% male) cases diagnosed with schizophrenia commencing monotherapy with a second-generation antipsychotic were included in this study. Next to baseline evaluation of sociodemographic and clinical data, the Positive and Negative Syndrome Scale (PANSS) was used at the beginning and after 2, 4, 8, 12, and 24 weeks of treatment. Blood samples were collected simultaneously to measure CRP levels, NLR, MLR, and SII. Linear mixed-effects models were used to investigate whether PANSS (sub)scores and inflammatory markers changed over time and whether they were associated with each other. We found a significant reduction of most PANSS (sub)scores from baseline to follow-up measurements, while CRP levels, NLR, MLR, and SSI did not change between measurements. Results did not show statistically significant associations between PANSS (sub)score changes and changes in markers of neuroinflammation. This was also true when controlling for sex, age, smoking status, and body-mass index. This study found no evidence of an association between the levels of peripheral inflammatory markers and disease severity in schizophrenia

Inflammation · Peripheral · Post-hoc analysis · Psychiatry · Psychopathology · Schizophrenia (object-oriented programming · Clinical Psychology · Inflammasome and immune disorders · Medicine · Psychology · Schizophrenia research and treatment · Tryptophan and brain disorders · Internal Medicine

• Schizophrenia

  Open Access•Mary J Owens, Michael J Owen et al.•The Lancet•2016

  Incluir item

• The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

  Stanley R Kay, Abraham Fiszbein et al.•Schizophrenia Bulletin•1987

  Incluir item

• Neutrophil-to-Lymphocyte Ratio Is Independently Associated With Severe Psychopathology in Schizophrenia and Is Changed by Antipsychotic Administration

  Open Access•Xia Zhou, Xiaolan Wang et al.•Frontiers in Psychiatry•2020

  Incluir item

• Neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; systemic immune-inflammatory Index

  Open Access•Ke Chen, Lina Wang et al.•Frontiers in Psychiatry•2025

  Incluir item

• C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review

  Open Access•Guillaume Fond, Christophe Lançon et al.•Frontiers in Psychiatry•2018

  Incluir item

• The Brief Psychiatric Rating Scale

  Open Access•John E Overall, Donald R Gorham•Psychological Reports•1962

  Incluir item